Cargando…

Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom

BACKGROUND: Several bone-targeted agents (BTAs) are available for preventing skeletal-related events (SREs), but they vary in terms of efficacy, safety and mode of administration. This study assessed data on European physicians’ treatment preferences for preventing SREs in patients with bone metasta...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Yi, Arellano, Jorge, Gatta, Francesca, Hechmati, Guy, Hauber, A. Brett, Mohamed, Ateesha F., Bahl, Amit, von Moos, Roger, Body, Jean-Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030781/
https://www.ncbi.nlm.nih.gov/pubmed/29970078
http://dx.doi.org/10.1186/s12913-018-3272-x
_version_ 1783337192735637504
author Qian, Yi
Arellano, Jorge
Gatta, Francesca
Hechmati, Guy
Hauber, A. Brett
Mohamed, Ateesha F.
Bahl, Amit
von Moos, Roger
Body, Jean-Jacques
author_facet Qian, Yi
Arellano, Jorge
Gatta, Francesca
Hechmati, Guy
Hauber, A. Brett
Mohamed, Ateesha F.
Bahl, Amit
von Moos, Roger
Body, Jean-Jacques
author_sort Qian, Yi
collection PubMed
description BACKGROUND: Several bone-targeted agents (BTAs) are available for preventing skeletal-related events (SREs), but they vary in terms of efficacy, safety and mode of administration. This study assessed data on European physicians’ treatment preferences for preventing SREs in patients with bone metastases from solid tumours. METHODS: Physicians completed a web-based discrete-choice experiment survey of 10 choices between pairs of profiles of hypothetical BTAs for a putative patient. Each profile included five attributes within a pre-defined range (primarily based on existing BTAs’ prescribing information): time (months) until the first SRE; time (months) until worsening of pain; annual risk of osteonecrosis of the jaw (ONJ); annual risk of renal impairment; and mode of administration. Choice questions were developed using an experimental design with known statistical properties. A separate main-effects random parameters logit model was estimated for each country and provided the relative preference for the treatment attributes in the study. RESULTS: A total of 191 physicians in France, 192 physicians in Germany, and 197 physicians in the United Kingdom completed the survey. In France and the United Kingdom, time until the first SRE and risk of renal impairment were the most important attributes; in Germany, time until the first SRE and delay in worsening of pain were the most important. In all countries, a 120-min infusion every 4 weeks was the least preferred mode of administration (p < 0.05) and the annual risk of ONJ was judged to be the least important attribute. CONCLUSIONS: When making treatment decisions regarding the choice of BTA, delaying the onset of SREs/worsening of pain and reducing the risk of renal impairment are the primary objectives for physicians.
format Online
Article
Text
id pubmed-6030781
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60307812018-07-09 Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom Qian, Yi Arellano, Jorge Gatta, Francesca Hechmati, Guy Hauber, A. Brett Mohamed, Ateesha F. Bahl, Amit von Moos, Roger Body, Jean-Jacques BMC Health Serv Res Research Article BACKGROUND: Several bone-targeted agents (BTAs) are available for preventing skeletal-related events (SREs), but they vary in terms of efficacy, safety and mode of administration. This study assessed data on European physicians’ treatment preferences for preventing SREs in patients with bone metastases from solid tumours. METHODS: Physicians completed a web-based discrete-choice experiment survey of 10 choices between pairs of profiles of hypothetical BTAs for a putative patient. Each profile included five attributes within a pre-defined range (primarily based on existing BTAs’ prescribing information): time (months) until the first SRE; time (months) until worsening of pain; annual risk of osteonecrosis of the jaw (ONJ); annual risk of renal impairment; and mode of administration. Choice questions were developed using an experimental design with known statistical properties. A separate main-effects random parameters logit model was estimated for each country and provided the relative preference for the treatment attributes in the study. RESULTS: A total of 191 physicians in France, 192 physicians in Germany, and 197 physicians in the United Kingdom completed the survey. In France and the United Kingdom, time until the first SRE and risk of renal impairment were the most important attributes; in Germany, time until the first SRE and delay in worsening of pain were the most important. In all countries, a 120-min infusion every 4 weeks was the least preferred mode of administration (p < 0.05) and the annual risk of ONJ was judged to be the least important attribute. CONCLUSIONS: When making treatment decisions regarding the choice of BTA, delaying the onset of SREs/worsening of pain and reducing the risk of renal impairment are the primary objectives for physicians. BioMed Central 2018-07-03 /pmc/articles/PMC6030781/ /pubmed/29970078 http://dx.doi.org/10.1186/s12913-018-3272-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Qian, Yi
Arellano, Jorge
Gatta, Francesca
Hechmati, Guy
Hauber, A. Brett
Mohamed, Ateesha F.
Bahl, Amit
von Moos, Roger
Body, Jean-Jacques
Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
title Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
title_full Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
title_fullStr Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
title_full_unstemmed Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
title_short Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
title_sort physicians’ preferences for bone metastases treatments in france, germany and the united kingdom
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030781/
https://www.ncbi.nlm.nih.gov/pubmed/29970078
http://dx.doi.org/10.1186/s12913-018-3272-x
work_keys_str_mv AT qianyi physicianspreferencesforbonemetastasestreatmentsinfrancegermanyandtheunitedkingdom
AT arellanojorge physicianspreferencesforbonemetastasestreatmentsinfrancegermanyandtheunitedkingdom
AT gattafrancesca physicianspreferencesforbonemetastasestreatmentsinfrancegermanyandtheunitedkingdom
AT hechmatiguy physicianspreferencesforbonemetastasestreatmentsinfrancegermanyandtheunitedkingdom
AT hauberabrett physicianspreferencesforbonemetastasestreatmentsinfrancegermanyandtheunitedkingdom
AT mohamedateeshaf physicianspreferencesforbonemetastasestreatmentsinfrancegermanyandtheunitedkingdom
AT bahlamit physicianspreferencesforbonemetastasestreatmentsinfrancegermanyandtheunitedkingdom
AT vonmoosroger physicianspreferencesforbonemetastasestreatmentsinfrancegermanyandtheunitedkingdom
AT bodyjeanjacques physicianspreferencesforbonemetastasestreatmentsinfrancegermanyandtheunitedkingdom